27 Citations (Scopus)

Abstract

Background: Salivary duct carcinoma (SDC) is a rare malignancy with a poor prognosis. Human epidermal growth factor receptor-2 (Her-2/neu) is overexpressed in SDC and, hence, HER-2/neu targeted therapy could be an option. Methods: A 72-year-old man presented with parotid swelling and cervical lymphadenopathy. He underwent a parotidectomy, modified radical neck dissection, and postoperative chemoradiation with cisplatin. A year later, he developed metastatic disease in the contralateral neck that was treated surgically with right axillary lymphadenopathy. He received radiation to both sites, concurrent with carboplatin. Two years later, he underwent resection of a lung metastasis. He then had progression in the axillary and mediastinal lymph nodes and received 5 cycles of docetaxel and trastuzumab followed by maintenance trastuzumab. Results: The patient had a partial response and restaging studies 9 months after therapy discontinuation did not show progression. Conclusion: Trastuzumab-based therapy is a potential therapeutic option for patients with SDC.

Original languageEnglish (US)
Pages (from-to)E372-E375
JournalHead and Neck
Volume35
Issue number12
DOIs
StatePublished - Dec 1 2013

Fingerprint

Salivary Ducts
Carcinoma
docetaxel
Neck Dissection
Carboplatin
Therapeutics
Cisplatin
Neck
Lymph Nodes
Maintenance
Radiation
Neoplasm Metastasis
Lung
Trastuzumab
Neoplasms
Lymphadenopathy

Keywords

  • HER-2/neu
  • chemotherapy
  • salivary duct carcinoma
  • survival
  • trastuzumab

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Salivary duct carcinoma responding to trastuzumab-based therapy : Case report and review of the literature. / Krishnamurthy, Jairam; Krishnamurty, Devi Mukkai; Baker, John J; Zhen, Weining; Lydiatt, Daniel; Ganti, Apar Kishor P.

In: Head and Neck, Vol. 35, No. 12, 01.12.2013, p. E372-E375.

Research output: Contribution to journalArticle

Krishnamurthy, Jairam ; Krishnamurty, Devi Mukkai ; Baker, John J ; Zhen, Weining ; Lydiatt, Daniel ; Ganti, Apar Kishor P. / Salivary duct carcinoma responding to trastuzumab-based therapy : Case report and review of the literature. In: Head and Neck. 2013 ; Vol. 35, No. 12. pp. E372-E375.
@article{f3c1f9fc63604c879f89515244ead2d9,
title = "Salivary duct carcinoma responding to trastuzumab-based therapy: Case report and review of the literature",
abstract = "Background: Salivary duct carcinoma (SDC) is a rare malignancy with a poor prognosis. Human epidermal growth factor receptor-2 (Her-2/neu) is overexpressed in SDC and, hence, HER-2/neu targeted therapy could be an option. Methods: A 72-year-old man presented with parotid swelling and cervical lymphadenopathy. He underwent a parotidectomy, modified radical neck dissection, and postoperative chemoradiation with cisplatin. A year later, he developed metastatic disease in the contralateral neck that was treated surgically with right axillary lymphadenopathy. He received radiation to both sites, concurrent with carboplatin. Two years later, he underwent resection of a lung metastasis. He then had progression in the axillary and mediastinal lymph nodes and received 5 cycles of docetaxel and trastuzumab followed by maintenance trastuzumab. Results: The patient had a partial response and restaging studies 9 months after therapy discontinuation did not show progression. Conclusion: Trastuzumab-based therapy is a potential therapeutic option for patients with SDC.",
keywords = "HER-2/neu, chemotherapy, salivary duct carcinoma, survival, trastuzumab",
author = "Jairam Krishnamurthy and Krishnamurty, {Devi Mukkai} and Baker, {John J} and Weining Zhen and Daniel Lydiatt and Ganti, {Apar Kishor P}",
year = "2013",
month = "12",
day = "1",
doi = "10.1002/hed.23307",
language = "English (US)",
volume = "35",
pages = "E372--E375",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Salivary duct carcinoma responding to trastuzumab-based therapy

T2 - Case report and review of the literature

AU - Krishnamurthy, Jairam

AU - Krishnamurty, Devi Mukkai

AU - Baker, John J

AU - Zhen, Weining

AU - Lydiatt, Daniel

AU - Ganti, Apar Kishor P

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Background: Salivary duct carcinoma (SDC) is a rare malignancy with a poor prognosis. Human epidermal growth factor receptor-2 (Her-2/neu) is overexpressed in SDC and, hence, HER-2/neu targeted therapy could be an option. Methods: A 72-year-old man presented with parotid swelling and cervical lymphadenopathy. He underwent a parotidectomy, modified radical neck dissection, and postoperative chemoradiation with cisplatin. A year later, he developed metastatic disease in the contralateral neck that was treated surgically with right axillary lymphadenopathy. He received radiation to both sites, concurrent with carboplatin. Two years later, he underwent resection of a lung metastasis. He then had progression in the axillary and mediastinal lymph nodes and received 5 cycles of docetaxel and trastuzumab followed by maintenance trastuzumab. Results: The patient had a partial response and restaging studies 9 months after therapy discontinuation did not show progression. Conclusion: Trastuzumab-based therapy is a potential therapeutic option for patients with SDC.

AB - Background: Salivary duct carcinoma (SDC) is a rare malignancy with a poor prognosis. Human epidermal growth factor receptor-2 (Her-2/neu) is overexpressed in SDC and, hence, HER-2/neu targeted therapy could be an option. Methods: A 72-year-old man presented with parotid swelling and cervical lymphadenopathy. He underwent a parotidectomy, modified radical neck dissection, and postoperative chemoradiation with cisplatin. A year later, he developed metastatic disease in the contralateral neck that was treated surgically with right axillary lymphadenopathy. He received radiation to both sites, concurrent with carboplatin. Two years later, he underwent resection of a lung metastasis. He then had progression in the axillary and mediastinal lymph nodes and received 5 cycles of docetaxel and trastuzumab followed by maintenance trastuzumab. Results: The patient had a partial response and restaging studies 9 months after therapy discontinuation did not show progression. Conclusion: Trastuzumab-based therapy is a potential therapeutic option for patients with SDC.

KW - HER-2/neu

KW - chemotherapy

KW - salivary duct carcinoma

KW - survival

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84888002215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888002215&partnerID=8YFLogxK

U2 - 10.1002/hed.23307

DO - 10.1002/hed.23307

M3 - Article

C2 - 23765450

AN - SCOPUS:84888002215

VL - 35

SP - E372-E375

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 12

ER -